You need to repeat it yearly. Multitarget stool DNA test (Cologuard) This combines testing for blood with testing for DNA or gene changes in cells that can get into your poop from polyps ...

Exact Sciences rose Friday after the Food and Drug Administration approved its next-generation colon cancer detection test, ...

Medically reviewed by Steffini Stalos, DOFact checked by Nick BlackmerMedically reviewed by Steffini Stalos, DOFact checked ...

That’s why timely screening should be part of your regular health check-upPurdue University’s Center for Healthy Living (CHL), in conjunction with Cologuard® and Exact Sciences, is providing no-cost, ...

The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.

The blood is tested for biomarkers and DNA mutations that are present with cancer. Another option, Cologuard, can be done at home — you collect a sample of your stool and mail it to a lab with ...

The FDA has approved the Cologuard Plus test for colorectal cancer screening in adults aged 45 years at average risk for colorectal cancer. The Food and Drug Administration (FDA) has approved the ...

Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize ...

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of ...

Puneet Souda’s rating is based on the expectation of broader adoption and higher volumes for Exact Sciences’s Cologuard Plus (CG+), which is anticipated to have higher specificity compared to ...

Mark Massaro has given his Buy rating due to a combination of factors including the recent FDA approval and anticipated superior performance of Exact Sciences’ Cologuard Plus test. The analyst ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...